Chronic Kidney Diseases, Safety Issues
Conditions
Keywords
patient safety, self-management, remote monitoring
Brief summary
The benefits of renin angiotensin system (RAS) blockers and diuretics for blood pressure control are well-established in chronic kidney diseases (CKD) patients; however, these agents may become hazardous on sick-days that lead to volume depletion (dehydration), and increase the risk of kidney function loss and acute kidney injury (AKI). It is not known how frequent significant sick-days occur in CKD patients, or whether a patient self-managed Sick-Day Protocol (SDP) that temporarily holds RAS blocker, diuretics, or other high risk medication in an effort to preserve renal function, or prevent AKI. The purpose of the study is to asses if a SDP, monitored remotely with a weekly automated phone survey , can improve outcomes in CKD (such as slow renal function loss and AKI episodes) and reduce preventable service utilization versus usual care.
Detailed description
Hypothesis: implementing a self managed Sick-Day Protocol with telephone monitoring via interactive voice survey dial-response system (IVSDRS) in CKD patients taking RAS blockers, diuretics, metformin, or NSAIDs, will safely slow renal function loss, reduce the incidence of acute kidney injury, and prevent urgent health utilization; in comparison to usual care. Study Design: 6-month randomized trial of Sick-Day Protocol vs usual care Randomization: In-block randomization stratified by use (with or without any other qualifying medication) vs non-use of RAS blocker (with any other qualifying medication) Intervention: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness), IVRSDRS remote monitoring, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC) Study Population: Veterans across the VA Maryland Health Care System (VAMCHS) with a current prescription for any type of RAS blocker, Diuretic, Metformin or NSAID. Study Site: Baltimore VA Medical Center (BVAMC), VA Geriatrics Research Education and Clinical Center (GRECC). Specific Aims 1: Conduct a pragmatic trial comparing the renal function decline, incidence of AKI, and urgent service utilization in eligible CKD patients provided with a self-managed Sick-Day Protocol versus comparable patients receiving usual care.Specific Aim 2: Determine the incidence of sick-days in the intervention arm using remote IVSDRS monitoring and end-of-study survey of all participants. Specific Aim 3: Evaluate intervention arm participants' usage of, and adherence to, the Sick-Day Protocol with remote IVSDRS monitoring. Study Measurements: laboratory-measured renal function, and patient- reported safety events obtained per IVSDRS protocol. Emergency department (ED) visits, hospitalization, renal progression, incidence of ESRD, and death will be measured in both groups along with patient satisfaction. Primary outcomes: 6-month change in renal function (eGFR), incidence of AKI episodes (including ICD-10 code designated, and detectable creatinine-based changes in renal function usingRIFLE criteria), preventable/urgent service utilization (to be ascertained using VA EHR review) Secondary outcomes: Determination of incidence of sick-day events (IVSDRS reporting, and end-of-study self-report). Tertiary:Adherence to self-management Sick-Day Protocol (based on IVSDRS reporting) Analytic plans: Comparison between intervention and usual care participants of 6-month renal function change, and frequency of AKI and hospitalization using generalized linear models and Poisson regression methods, respectively. Similar regression methods will be used to determine the adjusted frequency rate of sick-day incidents and participant response to sick-days. Public Health Relevance: Introduction of a self-management Sick-Day Protocol in conjunction with coordinated care and IVSDRS surveillance can be an innovative strategy to improve renal outcomes and reduce preventable service utilization.
Interventions
Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
Standard clinical care
Sponsors
Study design
Eligibility
Inclusion criteria
* Veterans with prescription for any type of RAS blocker, diuretic, Metformin or NSAID
Exclusion criteria
* Expected death or dialysis within 6 months * No home or cellular telephone
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Renal Function From Baseline to Study Completion; | 6 months (enrollment to study completion) | Laboratory measurement of creatinine at study entry and completion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Kidney Injury Incidents | 6 months (enrollment to study completion) | Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria |
| ER Use and Hospitalization | 6 months (enrollment to study completion) | Participants with urgent service utilization including emergency department, hospitalization, and urgent care. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Determination of Sick-day Incidents | 6 months from enrollment in study | Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment. |
| Adherence to the Self-management Sick-day Protocol | 6 months (enrollment to study completion) | Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sick-Day Protocol Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring | 159 |
| Usual Care Usual Care: Standard clinical care | 156 |
| Total | 315 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 3 | 2 |
| Overall Study | Lost to Follow-up | 3 | 7 |
| Overall Study | Randomized, but did not receive intervention. Withdrew prior to baseline visit. | 17 | 10 |
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Sick-Day Protocol | Usual Care | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 130 Participants | 119 Participants | 249 Participants |
| Age, Categorical Between 18 and 65 years | 29 Participants | 37 Participants | 66 Participants |
| eGFR | 43.110 ml/min/1.73m^2 STANDARD_DEVIATION 13.128 | 43.783 ml/min/1.73m^2 STANDARD_DEVIATION 13.018 | 43.441 ml/min/1.73m^2 STANDARD_DEVIATION 13.057 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 158 Participants | 155 Participants | 313 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 100 Participants | 99 Participants | 199 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 58 Participants | 56 Participants | 114 Participants |
| Region of Enrollment United States | 159 participants | 156 participants | 315 participants |
| Sex: Female, Male Female | 7 Participants | 7 Participants | 14 Participants |
| Sex: Female, Male Male | 152 Participants | 149 Participants | 301 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 159 | 2 / 156 |
| other Total, other adverse events | 7 / 159 | 3 / 156 |
| serious Total, serious adverse events | 0 / 159 | 0 / 156 |
Outcome results
Change in Renal Function From Baseline to Study Completion;
Laboratory measurement of creatinine at study entry and completion
Time frame: 6 months (enrollment to study completion)
Population: 280 participants with complete laboratory data collection
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sick-Day Protocol | Change in Renal Function From Baseline to Study Completion; | 0.01 mg/dL |
| Usual Care | Change in Renal Function From Baseline to Study Completion; | 0.02 mg/dL |
Acute Kidney Injury Incidents
Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria
Time frame: 6 months (enrollment to study completion)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Sick-Day Protocol | Acute Kidney Injury Incidents | AKI ICD-10 code on ED visit or admission | 4 Participants |
| Sick-Day Protocol | Acute Kidney Injury Incidents | 50% increase in Creatinine | 1 Participants |
| Usual Care | Acute Kidney Injury Incidents | AKI ICD-10 code on ED visit or admission | 4 Participants |
| Usual Care | Acute Kidney Injury Incidents | 50% increase in Creatinine | 0 Participants |
ER Use and Hospitalization
Participants with urgent service utilization including emergency department, hospitalization, and urgent care.
Time frame: 6 months (enrollment to study completion)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Sick-Day Protocol | ER Use and Hospitalization | Hospitalization | 29 Participants |
| Sick-Day Protocol | ER Use and Hospitalization | Emergency Room | 35 Participants |
| Sick-Day Protocol | ER Use and Hospitalization | Urgent Care | 5 Participants |
| Usual Care | ER Use and Hospitalization | Hospitalization | 23 Participants |
| Usual Care | ER Use and Hospitalization | Emergency Room | 30 Participants |
| Usual Care | ER Use and Hospitalization | Urgent Care | 5 Participants |
Adherence to the Self-management Sick-day Protocol
Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)
Time frame: 6 months (enrollment to study completion)
Population: Sick-Day Protocol group
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Sick-Day Protocol | Adherence to the Self-management Sick-day Protocol | Followed Sick-Day Protocol instructions | 14 count of qualifying illnesses |
| Sick-Day Protocol | Adherence to the Self-management Sick-day Protocol | Did not stop medicines | 12 count of qualifying illnesses |
| Sick-Day Protocol | Adherence to the Self-management Sick-day Protocol | Stopped other medicines in addition to SDP qualifying. | 6 count of qualifying illnesses |
Determination of Sick-day Incidents
Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.
Time frame: 6 months from enrollment in study
Population: 299 participants who completed all study visits.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Sick-Day Protocol | Determination of Sick-day Incidents | 29 Participants |
| Usual Care | Determination of Sick-day Incidents | 20 Participants |